To determine whether these two genes are putatively involved in cisplatin resistance, their mRNA levels in 32 selected patients with different RFS rates after hospital treatment were determined. Based on the RT-qPCR results, patients with shorter RFS (RFS <12 months, no. 01-019) had significantly higher SMARCA2 and CAMK2D levels, compared to those with longer RFS (RFS >12 months, no. 1-13; Fig. 2C).

CAMK2D and SMARCA2 were additionally overexpressed in another ovarian cancer cell line, SKVO3, to validate their effects. The survival rate of cisplatin-treated cells increased from 20 to 25% in SKVO3-CAMK2D and 38% in SKVO3-SMARCA2 (Fig. 3C and D). Data from cell viability analyses in both A2780 and SKVO3 cell lines indicate that overexpression of either CAMK2D or SMARCA2 increases cell resistance to cisplatin.